| Dr Robert Raymond Bates Jr, MD | |
|
1 Hospital Way, Crow Agency, MT 59022 | |
| (406) 638-3467 | |
| (406) 638-3569 |
| Full Name | Dr Robert Raymond Bates Jr |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 1 Hospital Way, Crow Agency, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780678326 | NPI | - | NPPES |
| 61554 | Other | GA | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 0101058393 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Raymond Bates Jr, MD Po Box 9, Crow Agency, MT 59022-0009 Ph: (406) 638-3467 | Dr Robert Raymond Bates Jr, MD 1 Hospital Way, Crow Agency, MT 59022 Ph: (406) 638-3467 |
News Archive
Flamel Technologies announced today that it has entered into a license agreement with a leading specialty pharmaceutical company for development and commercialization of two molecules for pain indications.
AAPC announced its 2012 medical coding books pre-sale through June 30, and once again lowered prices from the previous year. Prices have been reduced more than 55 percent over competitive publishers.
Today, Cancer Research UK, the world's largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents and tools, are pleased to announce a new partnership for the development and commercialization of novel custom antibodies to support the acceleration of cancer research.
A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.
› Verified 7 days ago